Brookfield, a global alternative asset manager, has agreed to purchase Antylia Scientific, a specialist in laboratory equipment, for $1.4 billion, according to Financial Times, citing sources familiar with the matter. This acquisition marks the end of GTCR’s intermittent ownership of the company over the past decade. GTCR initially separated Antylia from the larger Thermo Fisher Scientific (NYSE: TMO ) in 2014.

The transaction, which also involves Antylia’s minority stakeholders Golden Gate Capital and the management team, was finalized in the preceding weeks. The announcement of the deal is anticipated soon, barring any unforeseen complications.

Goldman Sachs and Jefferies provided financial advice for the sale, underscoring the significance of the transaction in the private capital market. The acquisition of Antylia Scientific by Brookfield indicates a strategic expansion within the laboratory equipment sector.

Antylia Scientific has established a reputation for providing critical tools and services for the life sciences industry. The deal with Brookfield is expected to provide the company with a robust platform for future growth and expansion.

The acquisition is part of a broader trend of investment firms showing keen interest in the life sciences sector, which has seen a surge in demand partly due to the global health challenges and advancements in biotechnology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.